Wexford Capital’s Kyntra Bio KYNB Stock Holding History

Wexford Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,288	Closed	-$28.5K	–	241
2023 Q4	$28.5K	Buy	+1,288	New	+$19.4K	0.01%	164

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wexford Capital's KYNB Position: Q1 2024 in Review

Wexford Capital sold out of Kyntra Bio (KYNB) in Q1 2024, closing a stake of 1,288 shares — an estimated $28.5K sold.

Wexford Capital first reported a position in KYNB in Q4 2023 and held it in 1 quarter. The position peaked at $28.5K in Q4 2023. 112 funds tracked by Wall St. Rank hold KYNB as of Q1 2024.

Wexford Capital reported no remaining Kyntra Bio position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 1,288 Kyntra Bio shares in Q1 2024, an estimated $28.5K.
Wexford Capital first reported a position in Kyntra Bio in Q4 2023 and held it in 1 quarter.
Wexford Capital's Kyntra Bio position peaked at $28.5K in Q4 2023.
112 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.